Lipocine surges after Canada approves co's testosterone replacement therapy
BUZZ-Lipocine surges after Canada approves co's testosterone replacement therapy ** Shares of drugmaker Lipocine LPCN.O rise 28% to $2.7 premarket
** LPCN says Health Canada has approved its oral testosterone replacement therapy Tlando for male hypogonadism
** Lipocine licensed the US and Canadian commercial rights of Tlando to privately held Verity Pharma in January 2024
** Lipocine is eligible for up to $259 million in milestone payments as well as royalty payments in the range of 12% to 18% on net sales of Tlando
** More than 700,000 prescriptions are written annually in Canada for TRT, and about 50% of this patient population is covered through private insurance, according to Lipocine
** TRT treatments are available in several forms, including injections, oral therapies and topical creams
** As of last close, LPCN stock was down 73% YTD
(Reporting by Padmanabhan Ananthan)
Recent news on Lipocine
See all newsUS STOCKS ON THE MOVE-Halozyme, Moderna, Merck
U.S. STOCKS ON THE MOVE-Halozyme, BKV, AppFolio
U.S. STOCKS ON THE MOVE-Hecla Mining, XPO, Lipocine
Lipocine surges after Canada approves co's testosterone replacement therapy
Brief: Lipocine Announces Health Canada Approval Of Tlando For Testosterone Replacement Therapy